INGENITO GARY

Chief Med. & Reg. Officer sells 244,000 shares (78% of holdings) for $5.8M at $23.67–$23.68 avg

Gary Ingenito executed 2 separate sales totaling 244,000 shares for $5,775,720.00, reducing his CPRX holdings from 312,873 shares to 68,873 shares — a 78.0% reduction in stake. The sales occurred at $23.68 on 2025-05-13 and $23.63 on 2025-05-14, near the stock's 52-week high of $25.74 (current price $23.78 is 7.6% below peak). At the same-ticker level, Ingenito's 4 prior CPRX sells show mixed timing: two recent sales (2025-03-05 and 2025-03-06) posted 30-day gains of +4.4% and +6.5%, while his 2024 sales displayed an 0-of-2 well-timed rate at the 90-day horizon, suggesting stock strength after his prior exits. Against favorable fundamentals (P/E 14.68, +23.5% annual revenue growth, $56.7M net income), the substantial reduction in executive stake warrants investor attention to underlying conviction and capital allocation timing.

CPRX CMO Gary Ingenito sold 225,000 shares (76.6% reduction) for $4,894,609.68 across two trades at $22.09–$21.67 on Mar 5–6, 2025.

Gary Ingenito, Chief Medical and Regulatory Officer of Catalyst Pharmaceuticals, executed two separate sales on March 5–6, 2025, totaling 225,000 shares (225.0K shares) for $4,894,609.68, reducing his holdings from 293,873 shares to 68,873 shares—a 76.6% net reduction. The blended average sale price of $21.75 is slightly below the current price of $21.96, and the stock is trading 8.4% below its 52-week high of $23.96. At the same-ticker level, Ingenito's two prior sales at CPRX (August 2024 and June 2024) showed average 90-day returns of +25.5% and +22.2% respectively—both poorly-timed exits, as the stock continued to rise after he sold. The company's fundamentals remain solid (P/E 11.32, +23.5% annual revenue growth, $128.7M quarterly revenue, $43.9M net income), suggesting this large reduction is not driven by deterioration in the underlying business.

Chief Med. & Reg. Officer Gary Ingenito sold 100,000 shares (66.1% of holdings) at $18.04 on 2024-08-09; stock now at $19.59.

Gary Ingenito, Chief Medical & Regulatory Officer, liquidated 66.1% of his CPRX position, reducing holdings from 151,391 shares to 51,391 shares via a single open-market sale of 100,000 shares at $18.04 on 2024-08-09. The stock has since appreciated to $19.59 (+8.6% above the sale price), and currently trades at the 52-week high of $19.59 after a 30-day gain of 18.2% and 90-day gain of 17.6%. His cross-ticker track record shows 1 prior sell with a 30-day average return of -6.0%, and his CPRX-specific history includes one prior sale on 2024-06-05 that posted a -6.0% 30-day return. The sale occurs amid strong financial performance: the company reported revenue of $122,710,000.00 and net income of $40,794,000.00 in the latest quarter, with 85.9% annual revenue growth and a market cap of $2,325,095,902.23. The magnitude of the reduction—selling roughly two-thirds of holdings—is material and differs from minor portfolio adjustments; investors should track whether this represents a shift in the executive's conviction regarding the company's trajectory.